BR112013023038A2 - composto e uso de um composto - Google Patents

composto e uso de um composto

Info

Publication number
BR112013023038A2
BR112013023038A2 BR112013023038A BR112013023038A BR112013023038A2 BR 112013023038 A2 BR112013023038 A2 BR 112013023038A2 BR 112013023038 A BR112013023038 A BR 112013023038A BR 112013023038 A BR112013023038 A BR 112013023038A BR 112013023038 A2 BR112013023038 A2 BR 112013023038A2
Authority
BR
Brazil
Prior art keywords
compound
Prior art date
Application number
BR112013023038A
Other languages
English (en)
Other versions
BR112013023038B1 (pt
Inventor
Hajime Yamada
Hitomi Aoki
Junya Tagashira
Rie Ishida
Ryohei Sekimoto
Seiichi Sato
Tadaaki Ohgiya
Toru Miura
Toshiaki Watanabe
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of BR112013023038A2 publication Critical patent/BR112013023038A2/pt
Publication of BR112013023038B1 publication Critical patent/BR112013023038B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112013023038A 2011-03-14 2012-03-13 composto e uso de um composto BR112013023038B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011055691 2011-03-14
PCT/JP2012/001709 WO2012124311A1 (ja) 2011-03-14 2012-03-13 新規なフェニルピリジン誘導体及びこれを含有する医薬

Publications (2)

Publication Number Publication Date
BR112013023038A2 true BR112013023038A2 (pt) 2016-12-13
BR112013023038B1 BR112013023038B1 (pt) 2019-09-03

Family

ID=46830402

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013023038A BR112013023038B1 (pt) 2011-03-14 2012-03-13 composto e uso de um composto

Country Status (22)

Country Link
US (1) US9315493B2 (pt)
EP (1) EP2687523B1 (pt)
JP (1) JP5583841B2 (pt)
KR (1) KR101559307B1 (pt)
CN (1) CN103459380B (pt)
AU (1) AU2012227763B2 (pt)
BR (1) BR112013023038B1 (pt)
CA (1) CA2830043C (pt)
CY (1) CY1117348T1 (pt)
DK (1) DK2687523T3 (pt)
EA (1) EA026694B1 (pt)
ES (1) ES2562994T3 (pt)
HK (1) HK1189232A1 (pt)
HU (1) HUE028252T2 (pt)
MX (1) MX349697B (pt)
PL (1) PL2687523T3 (pt)
PT (1) PT2687523E (pt)
RS (1) RS54666B1 (pt)
SG (1) SG193477A1 (pt)
TW (1) TWI525088B (pt)
WO (1) WO2012124311A1 (pt)
ZA (1) ZA201307333B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103690955B (zh) * 2013-12-27 2016-04-20 福州乾正药业有限公司 含有替格瑞洛的药物组合物及其制备方法和药物应用
WO2019117291A1 (ja) * 2017-12-14 2019-06-20 興和株式会社 医薬組成物
CN115138481B (zh) * 2022-07-06 2024-01-26 中南大学 一种将方铅矿、闪锌矿中的至少一种矿物与辉钼矿浮选分离的药剂和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5331165A (en) * 1976-09-03 1978-03-24 Iseki Kaihatsu Koki Continuous specific gravity meter
JPS5779456A (en) * 1980-11-06 1982-05-18 Fujitsu Ltd Voltage readout system by electron beam
JPS6211845A (ja) * 1985-07-10 1987-01-20 Sharp Corp 複写装置
US5472967A (en) 1991-02-20 1995-12-05 Synthelabo 4-pyrimidinone derivatives their preparation and their application in therapy
EP0514192A1 (en) * 1991-05-16 1992-11-19 Glaxo Group Limited Antihypertensive benzofuran derivatives, substituted by varied N-pyrimidinyl- or N-imidazolyl-methyl groups
CN1079223A (zh) * 1991-05-16 1993-12-08 格拉克索公司 苯并呋喃衍生物
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
US5212177A (en) * 1991-12-16 1993-05-18 E. R. Squibb & Sons, Inc. Indole and benzimidazole-substituted dihydropyrimidine derivatives
JPH07179456A (ja) * 1993-12-21 1995-07-18 Nkk Corp アルキルベンゾフラン誘導体及びアンジオテンシンｉｉ拮抗剤
IT1273790B (it) 1994-02-18 1997-07-10 Guidotti & C Spa Labor Derivati eterociclici diazotati aventi attivita' aii antagonista
CN101589037A (zh) * 2006-11-24 2009-11-25 武田药品工业株式会社 杂单环化合物及其用途
JP2010510962A (ja) * 2006-11-24 2010-04-08 武田薬品工業株式会社 複素単環化合物およびその用途
AU2007343139A1 (en) 2006-12-21 2008-07-17 Pfizer Products Inc. Compounds having both angiotensin II receptor antagonism and PPARy activating activities
EP1988091B1 (en) 2007-02-07 2015-06-10 Kyowa Hakko Kirin Co., Ltd. Tricyclic compounds
WO2008096820A1 (ja) 2007-02-07 2008-08-14 Kyowa Hakko Kirin Co., Ltd. ビフェニル誘導体
WO2008143262A1 (ja) 2007-05-21 2008-11-27 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
TW201031659A (en) * 2009-02-23 2010-09-01 Kowa Co Novel compound having 3-(5-alkoxypyrimidin-2-yl) pyrimidin-4(3H)-on structure and medicine containg same
WO2010119700A1 (ja) * 2009-04-17 2010-10-21 興和株式会社 新規な３-ヘテロアリールピリミジン-４-(３ｈ)-オン構造を有する化合物及びこれを含有する医薬
TWI500611B (zh) * 2009-09-29 2015-09-21 Kowa Co 新穎苯基吡啶衍生物及含有該衍生物之醫藥

Also Published As

Publication number Publication date
EA201391314A1 (ru) 2014-02-28
JP5583841B2 (ja) 2014-09-03
ES2562994T3 (es) 2016-03-09
PT2687523E (pt) 2016-03-31
HUE028252T2 (en) 2016-12-28
ZA201307333B (en) 2015-01-28
EP2687523A4 (en) 2014-11-12
EP2687523B1 (en) 2016-01-06
KR20140008431A (ko) 2014-01-21
WO2012124311A8 (ja) 2013-05-10
BR112013023038B1 (pt) 2019-09-03
AU2012227763A1 (en) 2013-10-24
EA026694B1 (ru) 2017-05-31
US20140011823A1 (en) 2014-01-09
TWI525088B (zh) 2016-03-11
CN103459380B (zh) 2015-07-15
AU2012227763B2 (en) 2016-01-14
TW201245180A (en) 2012-11-16
US9315493B2 (en) 2016-04-19
MX349697B (es) 2017-08-09
EP2687523A1 (en) 2014-01-22
RS54666B1 (en) 2016-08-31
MX2013010553A (es) 2013-10-28
JPWO2012124311A1 (ja) 2014-07-17
NZ616158A (en) 2015-07-31
CY1117348T1 (el) 2017-04-26
HK1189232A1 (zh) 2014-05-30
WO2012124311A1 (ja) 2012-09-20
CA2830043C (en) 2018-06-05
SG193477A1 (en) 2013-10-30
CN103459380A (zh) 2013-12-18
KR101559307B1 (ko) 2015-10-12
CA2830043A1 (en) 2012-09-20
DK2687523T3 (en) 2016-03-14
PL2687523T3 (pl) 2016-06-30
AU2012227763A2 (en) 2013-11-14
AU2012227763A8 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
BR112014000260A2 (pt) composto, e, uso de um composto
BR112014013760A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014001255A2 (pt) composto, uso de um composto, combinação, e, composição farmacêutica
BR112014001346A2 (pt) composto nanotransportador, método, composto farmacêutico e uso de um composto
CO6801774A2 (es) Compuestos de benzotiazol y su uso farmacéutico
CO6930362A2 (es) Compuesto heterocíclico y su uso
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014029530A2 (pt) compostos, composição farmacêutica e uso de um composto
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
BR112012019936A2 (pt) uso de um composto, método de preparação de um composto, método e composto
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112013029206A2 (pt) composto, e, uso de um composto
BR112013030302A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014013177A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014007641A2 (pt) uso de um biocida
BR112014013660A2 (pt) uso de uma partícula
BR112014011685A2 (pt) composto, utilização de um composto e método
BR112014016635A2 (pt) composto, composição, e, uso de um composto
BR112014013178A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014009471A2 (pt) compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
BR112013025299A2 (pt) conjunto de ancoragem
BR112014014232A2 (pt) composto e método para a preparação de um composto
BR112014000015A2 (pt) formulação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/03/2012, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/03/2012, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 10A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2662 DE 11-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.